Last updated: February 21, 2026
What is NDC 72603-0319?
NDC 72603-0319 corresponds to a specific pharmaceutical product identified by the National Drug Code (NDC). Based on available databases, this NDC is associated with Apretude (cabotegravir extended-release injectable suspension), a long-acting injectable medication indicated for HIV pre-exposure prophylaxis (PrEP).
Market Context and Demand Drivers
HIV Prevention Market Overview
The global HIV PrEP market has experienced consistent growth, driven by increased awareness, expanding insurance coverage, and approval of new formulations. The key segments include:
- High-risk populations: Men who have sex with men, transgender individuals, and serodiscordant couples.
- Healthcare settings: Clinics specializing in infectious disease management.
- Geographies: North America dominates with over 70% of the market, followed by Europe and emerging markets.
Market Size and Growth Trends
| Year |
Market Size (USD billion) |
CAGR (2018-2025) |
| 2018 |
1.1 |
12% |
| 2020 |
1.4 |
|
| 2022 |
1.8 |
|
| 2025 (projected) |
3.0 |
|
Source: IQVIA, 2022; Bloomberg Intelligence, 2023.
Key Factors Influencing Demand
- Approval and adoption of long-acting formulations (like cabotegravir)
- Price reductions improving accessibility
- Policy shifts supporting HIV prevention programs
- Production capacity expansions
Competitive Landscape
Major Players
- ViiV Healthcare: Developer and manufacturer of Apretude.
- Gilead Sciences: Provider of oral PrEP options, competitive with Paxlovid.
- Generic providers: Potential entry as patents expire.
Key Differentiators
- Administration: Injectable, bi-monthly dosing.
- Efficacy: Higher adherence rates compared to oral PrEP.
- Side effects: Well characterized, with a manageable profile.
Price Analysis and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximate list price for Apretude is USD 3,600 per dose.
- Average sales price (ASP): Estimated USD 3,200, considering discounts and rebates.
- Per-year cost: Two injections, USD 6,400 annually per patient.
Market Penetration and Revenue Estimates (2023-2027)
| Year |
Estimated Patients (000s) |
Total Revenue (USD millions) |
Assumed Pricing (USD) |
Market Share of PrEP Market |
| 2023 |
50 |
160 |
3,200 |
20% |
| 2024 |
100 |
320 |
3,200 |
40% |
| 2025 |
150 |
480 |
3,200 |
60% |
| 2026 |
200 |
640 |
3,200 |
70% |
| 2027 |
250 |
800 |
3,200 |
75% |
Assumptions:
- Growth driven by increased adoption and expanding access in underserved markets.
- Price remains stable with slight reductions due to generic competition in 2028.
Price Trends and Outlook
- Short-term (2023-2025): Prices are expected to stabilize around current levels due to limited competition and high demand.
- Medium-term (2026-2028): Introduction of generics or biosimilars may reduce prices by 15-25%, leading to lower per-patient costs.
- Long-term (post-2028): Competitive pressures could lower prices further, potentially to USD 2,500 per dose.
Regulatory and Policy Impact
Pending and Recent Approvals
- Approval status varies by jurisdiction; FDA approved Apretude in December 2021.
- Pending approval in Europe, Latin America, and Asia.
- Reimbursement policies and insurance coverage significantly influence market access.
Policy Trends Affecting Prices
- Increased funding for HIV prevention programs.
- Favorable reimbursement policies expand affordable access.
- Push for generic entries could catalyze price reductions.
Key Takeaways
- NDC 72603-0319, representing Apretude, operates within a fast-growing HIV PrEP market.
- Current list price approximates USD 3,600 per dose, with annual expenses near USD 6,400 per patient.
- Market growth expected to reach USD 3.0 billion by 2025, driven by increased prevalence and acceptance.
- Price stability persists through 2025; significant reductions anticipated post-2027 with generic entries.
- Regulatory, reimbursement, and policy developments will influence future pricing and market size.
Frequently Asked Questions
Q1: How does Apretude compare to oral PrEP options in terms of price and adherence?
A1: Apretude's per-dose cost is higher than daily oral PrEP, but less frequent dosing improves adherence, potentially reducing overall treatment costs.
Q2: What factors could accelerate price declines for NDC 72603-0319?
A2: Entry of generics, negotiated discounts, and increased market competition can drive prices lower.
Q3: What is the primary market for this drug?
A3: Developed countries, especially the US, represent the main market due to high HIV prevalence and established healthcare infrastructure.
Q4: Will insurance coverage significantly influence future market penetration?
A4: Yes. Expanded coverage and reimbursement policies will be critical to increasing access and adoption.
Q5: What risks could impact future revenue projections?
A5: Regulatory delays, patent challenges, emerging competing therapies, and shifts in policy could alter revenue streams.
References
[1] IQVIA. (2022). Global HIV market report.
[2] Bloomberg Intelligence. (2023). HIV pharmaceuticals market analysis.
[3] ViiV Healthcare. (2021). FDA approval announcement for Apretude.
[4] FDA. (2021). Drug approval packages — Apretude (cabotegravir).
[5] World Health Organization. (2022). Global HIV prevention strategies.
